pneumococcal recombinant vaccine (GSK 2189242A)
/ GSK
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 20, 2019
Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children
(clinicaltrials.gov)
- P2; N=1806; Completed; Sponsor: GlaxoSmithKline; Phase classification: P2/3 ➔ P2
Clinical • Phase classification
February 16, 2019
Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children
(clinicaltrials.gov)
- P2/3; N=1806; Completed; Sponsor: GlaxoSmithKline; Phase classification: P2 ➔ P2/3
Phase classification
1 to 2
Of
2
Go to page
1